Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 6/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
| ▸ | USP1 | O94782 | 7/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15204215 | 0.87 | CHRM1 (0.43) | CHRM1DRD2DRD4DRD3BUB1 | |
| SCHEMBL3785133 | 0.82 | CHRM1 (0.68) | CHRM1DRD2DRD4DRD3BUB1 | |
| SCHEMBL13153318 | 0.80 | CHRM1 (0.43) | CHRM1DRD2DRD4DRD3BUB1 | |
| SCHEMBL614883 | 0.77 | CHRM1 (0.43) | CHRM1DRD2DRD4DRD3BUB1 | |
| SCHEMBL3785488 | 0.76 | CHRM1 (0.49) | CHRM1DRD2DRD4DRD3BUB1 | |
| SCHEMBL615989 | 0.73 | CHRM1 (0.40) | CHRM1HCRTR1HCRTR2 | |
| SCHEMBL617325 | 0.72 | CHRM1 (0.44) | CHRM1USP1HCRTR1HCRTR2KDM4E | |
| SCHEMBL617431 | 0.70 | CHRM1 (0.43) | CHRM1BUB1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL6897301 | 0.69 | CHRM1 (0.52) | CHRM1DRD2DRD4DRD3BUB1 | |
| SCHEMBL11894855 | 0.68 | CHRM1 (1.00) | CHRM1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421366-B1 | HETEROCYCLIC FUSED CINNOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8293744-B2 | Heterocyclic fused cinnoline M1 receptor positive allosteric modulators | MERCK SHARP & DOHME CORP. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040978-A1 | Heterocyclic Fused Cinnoline M1 Receptor Positive Allosteric Modulators | CHRM1, CNR1, CHRNA7 | CHRM1 1/4885DRD2 169/4885DRD4 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.